<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Saxagliptin (Onglyza™) is a dipeptidyl peptidase-4 (DPP4) inhibitor for treating type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This open-label, randomized, 2-way crossover study in 20 healthy female subjects investigated the effect of saxagliptin on the pharmacokinetics (PK) of the active components of a combined oral contraceptive (<z:chebi fb="0" ids="28887">COC</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects received either <z:chebi fb="0" ids="28887">COC</z:chebi> (Ortho-<z:chebi fb="0" ids="37391">Cyclen</z:chebi>®) QD for 21 days, then 5 mg saxagliptin QD + <z:chebi fb="0" ids="28887">COC</z:chebi> QD for 21 days, or vice versa </plain></SENT>
<SENT sid="3" pm="."><plain>Coadministration of saxagliptin and <z:chebi fb="0" ids="28887">COC</z:chebi> did not alter the steady-state PK of the primary active <z:chebi fb="0" ids="50114">estrogen</z:chebi> (<z:chebi fb="0" ids="4903">ethinyl estradiol</z:chebi>) or <z:chebi fb="0" ids="50745">progestin</z:chebi> (norelgestromin) <z:chebi fb="0" ids="28887">COC</z:chebi> components </plain></SENT>
<SENT sid="4" pm="."><plain>The area under the concentration time curve (AUC) and peak plasma concentration (C(max) ) of an active metabolite of norelgestromin (<z:chebi fb="0" ids="7630">norgestrel</z:chebi>) were increased by 13% and 17%, respectively, a magnitude that was not considered clinically meaningful </plain></SENT>
<SENT sid="5" pm="."><plain>Coadministration of saxagliptin and <z:chebi fb="0" ids="28887">COC</z:chebi> in this study was generally well tolerated </plain></SENT>
<SENT sid="6" pm="."><plain>Saxagliptin can be co-prescribed with an <z:chebi fb="0" ids="50114">estrogen</z:chebi>/<z:chebi fb="0" ids="50745">progestin</z:chebi> combination for women taking oral contraceptive </plain></SENT>
</text></document>